Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The global burden of pulmonary hypertension in sickle cell disease: a systematic review and meta-analysis
source: Annals of Hematology
year: 2016
authors: Musa BM, Galadanci NA, Coker M, Bussell S, Aliyu MH
summary/abstract:Elevated tricuspid regurgitant jet velocity (TRJV) is a surrogate measure of pulmonary hypertension (PH) in persons with sickle cell disease (SCD). We sought to estimate the burden of PH in people living with sickle cell disease based on TRJV. From 2000 to 2015, we searched electronic databases for eligible publications and included 29 studies (n = 5358 persons). We used random effects modeling to determine the pooled estimate of elevated TRJV. The overall pooled prevalence of elevated TRJV was 23.5 %(95 % CI 19.5-27.4) in persons with SCD. The pooled prevalence of elevated TRJV in children and adults with SCD was 20.7 % (95 % CI 15.7–25.6) and 24.4 % (95 % CI 18.4-30.4), respectively. TRJV is prevalent among adults and children with SCD. Our finding support international recommendations that call for screening for PH in SCD patients.
organization: Bayero University/Aminu Kano Teaching Hospital; University of Maryland; Vanderbilt University School of Medicine, Nashville; Meharry Medical College, NashvilleDOI: 10.1007/s00277-016-2693-z
read more full text
+myBinderRelated Content
-
Virtual Reality Helps Reduce Pain Among Patients With Sickle Cell DiseaseImmersive virtual reality appeared effec...
-
Cardiovascular Complications and Risk of Death in Sickle-cell DiseaseIn sickle-cell disease, a point mutation...
-
Randomized Trials Needed to Assess Benefits of Salmonella Vaccines in SCD Patients, Study SaysRandomized controlled trials are needed ...
-
Patterns of opioid use in sickle cell diseasePain, the hallmark complication of sickl...
-
Living With Unpredictable Pain: A Sickle Cell Disease StoryGrowing up, Vismel Marquez wanted to joi...
-
Patient Perspective: The Journey of Pain in Sickle Cell Diseasehttps://www.youtube.com/watch?v=F4raFO0e...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.